缬沙坦联合辛伐他汀与氨氯地平联合阿托伐他汀治疗高血压伴高脂血症的临床疗效比较

Comparison of Clinical Efficacy of Valsartan Combined with Simvastatin and Amlodipine Combined with Atorvastatin in Treatment of Hypertension Complicated with Hyperlipidemia

目的:比较缬沙坦联合辛伐他汀与氨氯地平联合阿托伐他汀治疗高血压伴高脂血症的临床疗效。方法:选择2014年2月-2015年10月来我院就诊的100例高血压伴高脂血症的患者为研究对象,按照随机数字表法将其分为对照组(50例)与试验组(50例),对照组应用氨氯地平(5~10 mg,qd;1周后加量至10 mg,qd)联用阿托伐他汀钙(10~50 mg,qd;1周后调至20~50 mg,qd),试验组应用缬沙坦(80 mg,qd)联合辛伐他汀(40 mg,qd)治疗。两组疗程均为3个月,比较两组治疗前后血压、血脂变化及药物不良反应。结果:治疗3个月后,试验组收缩压、舒张压、脉压差、低密度胆固醇(LDL-C)、总胆固醇(TC)、三酰甘油(TG)均低于对照组,高密度胆固醇(HDL-C)水平高于对照组,两组比较差异均有统计学意义(P<0.05);两组不良反应比较差异无统计学意义(P>0.05)。结论:缬沙坦联合辛伐他汀可显著控制高血压伴高脂血症患者的血压水平,促进血脂代谢,且不良反应少,安全性高,值得临床推广应用。

Objective:To compare the clinical efficacy of valsartan combined with simvastatin and amlodipine combined with atorvastatin in the treatment of hypertension complicated with hyperlipidemia. Methods:100 cases of patient with hypertension accompanied with hyperlipidemia from our hospital from February 2014 to October 2015 were chosen as research object. According to the random number table, all patients were divided into control group(50 cases) and experiential group(50 cases), the control group was administrated amlodipine(5~10 mg, qd; added to 10 mg after one week, qd) combined with atorvastatin calcium(10~50 mg, qd; added to 20~50 mg after one week, qd) for treatment, and the experimental group was administrated valsartan(80 mg, qd)combined with simvastatin(40 mg, qd)for treatment. Set the courses of treatment for 3 months and the blood pressure, blood lipid changes and adverse reactions of drugs were compared before and after treatment. Results:After 3 months of treatment, the indicators including systolic blood pressure, diastolic blood pressure, pulse pressure, low density lipoprotein cholesterol(LDL-C), total cholesterol(TC), triglyceride(TG) in experimental group were lower than control group, high density lipoprotein cholesterol(HDL-C) level was higher than that of control group, with significant differences between the two groups(P<0.05). There was no significant difference in adverse reactions between the two groups(P>0.05). Conclusion:Valsartan combined with simvastatin can significantly control blood pressure levels, promote lipid metabolism of patients with hypertension complicated with hyperlipidemia, decrease the adverse reactions and show high safety. It is worthy of clinical application.